



Cohere Medicare Advantage Policy – Coronary Computed Tomography Angiography (CCTA), with or without Fractional Flow Reserve (FFR)

Clinical Guidelines for Medical Necessity Review

Version: 1.3

Revision Date: May 15, 2025

Important Notices

Notices & Disclaimers:

GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice. This policy may be superseded by existing and applicable Centers for Medicare & Medicaid Services (CMS) statutes.

©2025 Cohere Health, Inc. All Rights Reserved.

Other Notices:

HCPCS® and CPT® copyright 2025 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

Guideline Information:

Specialty Area: Diagnostic Imaging

Guideline Name: Cohere Medicare Advantage Policy - Coronary Computed Tomography Angiography (CCTA), with or without Fractional Flow Reserve (FFR)

Type: Adult (18+ yo) | Pediatric (0-17 yo)

Table of Contents

Important Notices	2
Table of Contents	3
Medical Necessity Criteria	4
Service: Coronary Computed Tomography Angiogram (CCTA) with or without Fractional Flow Reserve (FFR)	4
Benefit Category	4
Related CMS Documents	4
Recommended Clinical Approach	5
Evaluation of Clinical Benefits and Potential Harms	5
Medical Necessity Criteria	7
Indications	7
Non-Indications	8
Disclaimer on Radiation Exposure in Pediatric Population	9
Level of Care Criteria	10
Procedure Codes (CPT/HCPCS)	10
Medical Evidence	11
References	13
Clinical Guideline Revision History/Information	20

Medical Necessity Criteria

Service: Coronary Computed Tomography Angiogram (CCTA) with or without Fractional Flow Reserve (FFR)

Benefit Category

Not applicable.

Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service. [36-45](#)

Related CMS Documents

Please refer to the [CMS Medicare Coverage Database](#) for the most current applicable CMS National Coverage.

- [LCD Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(L38839\)](#)
- [LCD Non-Invasive Fractional Flow Reserve \(FFR\) for Stable Ischemic Heart Disease \(L38278\)](#)
- [LCD Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(L38613\)](#)
- [LCD Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(L38615\)](#)
- [LCD Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(L39075\)](#)
- [LCD Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(L38771\)](#)
- [LCD Cardiac Computed Tomography & Angiography \(CCTA\) \(L33423\)](#)
- [LCD Cardiac Computed Tomography \(CCT\) and Coronary Computed Tomography Angiography \(CCTA\) \(L33947\)](#)
- [LCD Coronary Computed Tomography Angiography \(CCTA\) \(L35121\)](#)
- [LCD Cardiac Computed Tomography \(CCT\) and Coronary Computed Tomography Angiography \(CCTA\) \(L33559\)](#)
- [Billing and Coding: Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(A58473\)](#)
- [Billing and Coding: Category III Codes \(A56902\)](#)
- [Billing and Coding: Non-Invasive Fractional Flow Reserve \(FFR\) for Stable Ischemic Heart Disease \(A58406\)](#)
- [Billing and Coding: Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(A58097\)](#)

- [Billing and Coding: Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(A58095\)](#)
- [Billing and Coding: Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(A58814\)](#)
- [Billing and Coding: Non-Invasive Fractional Flow Reserve \(FFR\) for Ischemic Heart Disease \(A58359\)](#)
- [Billing and Coding: Cardiac Computed Tomography & Angiography \(CCTA\) \(A56691\)](#)
- [Billing and Coding: Cardiac Computed Tomography \(CCT\) and Coronary Computed Tomography Angiography \(CCTA\) \(A56737\)](#)
- [Billing and Coding: Cardiac Computed Tomography \(CCT\) and Coronary Computed Tomography Angiography \(CCTA\) \(A56451\)](#)
- [Billing and Coding: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography \(AI-QCT\)/Coronary Plaque Analysis \(AI-CPA\) \(DA59813\)](#)
- [Billing and Coding: Coronary Computed Tomography Angiography \(CCTA\)\(A57552\)](#)

Recommended Clinical Approach

Computed tomography coronary angiography (CCTA) is a non-invasive alternative to cardiac catheterization performed with iodinated contrast. The radiologist may consider additional phases, dynamic sequences, positioning of the patient, and the use of markers. The referring clinician is responsible for the appropriate clinical indication in consultation with a cardiac imaging expert. The patient's pertinent medical history should justify the exam. The physician laboratory director should choose the scanning protocol for the study before the patient's arrival. Following a positive CCTA, non-invasive fractional flow reserve (FFR) may be medically necessary to guide decisions about invasive coronary angiography in patients with intermediate or high-risk coronary anatomy on imaging.¹⁻⁵ CT-FFR is not recommended in patients with complex congenital heart disease.

Evaluation of Clinical Benefits and Potential Harms

Cohere Health uses the criteria below to ensure consistency in reviewing the conditions to be met for coverage of computed tomography coronary angiography (CCTA). This process helps to prevent both incorrect denials and inappropriate approvals of medically necessary services. Specifically, limiting incorrect approvals reduces the risks associated with unnecessary

procedures, such as complications from surgery, infections, and prolonged recovery times.

The potential clinical harms of using these criteria may include:

- Inherent risk of procedure: There are inherent risks of imaging, including cumulative radiation exposure, contrast, allergy, nephrotoxicity, and contrast extravasation into surrounding tissues.^{24,29-31}
- Potential danger to pregnancy: CT imaging completed during pregnancy confers a dose of ionizing radiation to the fetus and is generally only utilized when the potential benefits of this specific imaging modality outweigh the risks to the pregnancy.³² Fetal risk includes fetal demise, intrauterine growth restriction, microcephaly, delayed intellectual development, risk of childhood cancer, and fetal thyroid injury.³²
- Increased healthcare costs and complications from the inappropriate use of additional interventions.²⁶

The clinical benefits of using these criteria include:

- Accuracy: CCTA has exceptional diagnostic accuracy, with a high degree of sensitivity (91%) and specificity (92%) for the detection of coronary artery disease.¹ Further, CCTA in conjunction with FFR holds increased sensitivity and specificity of diagnostic accuracy than standard CCTA alone.^{9,21}
- Noninvasive: As a cardiac imaging modality, CCTA is relatively noninvasive when compared to other modalities, such as invasive cardiac angiography (ICA).¹ It is widely accepted that noninvasive procedures are less costly, associated with fewer complications, and preferred by both patients and providers.^{27,28}
- Enhanced overall patient satisfaction and healthcare experience.

This policy includes provisions for expedited reviews and flexibility in urgent cases to mitigate risks of delayed access. Evidence-based criteria are employed to prevent inappropriate denials, ensuring that patients receive medically necessary care. The criteria aim to balance the need for effective treatment with the minimization of potential harms, providing numerous

clinical benefits in helping avoid unnecessary complications from inappropriate care.

In addition, the use of these criteria is likely to decrease inappropriate denials by creating a consistent set of review criteria, thereby supporting optimal patient outcomes and efficient healthcare utilization.

Medical Necessity Criteria

Indications

→ **Computed tomography coronary angiography (CCTA) with or without fractional flow reserve (FFR)** is considered appropriate if **ANY** of the following is **TRUE**^{3,6-12}:

- ◆ There is a suspicion of cardiac anomaly¹² including **ANY** of the following^{36,37}:
 - Evaluation of cardiac mass (suspected tumor or thrombus)
 - Evaluation of pericardial conditions (mass, constrictive pericarditis or complications of cardiac surgery)
 - Complex congenital heart disease (e.g., anomalies of coronary or pulmonary circulation, great vessels and cardiac chamber and valves); **OR**
- ◆ Possible acute coronary syndrome where standard diagnostic testing including EKG and cardiac enzymes are nondiagnostic or indeterminate for myocardial injury³⁶⁻³⁹; **OR**
- ◆ No known coronary artery disease (CAD) with an intermediate or high pre-test probability of obstructive CAD (based on the [CAD Consortium Calculator](#))³³ and **ANY** of the following^{3,12}:
 - Chest pain (or ischemic equivalent, including dyspnea) after an inconclusive or abnormal exercise ECG or stress imaging study; **OR**
 - Chest pain (or ischemic equivalent, including dyspnea) after a negative stress test but with high clinical suspicion of CAD; **OR**
 - Chest pain (or ischemic equivalent, including dyspnea); **OR**
- ◆ CAD is known and previously determined to be non-obstructive (less than 70%), but there has been a clinical change that suggests CAD in the native coronary arteries has progressed¹³; **OR**

- ◆ Previous coronary revascularization with bypass or percutaneous intervention was performed and there is a clinical change in cardiac status³⁸; **OR**
- ◆ New or unexplained cardiomyopathy with an ejection fraction less than 40%^{5,36}; **OR**
- ◆ Fractional Flow Reserve (FFR) is for **ANY** of the following^{20,21,40-45}:
 - For functional evaluation of coronary CTA lesions, which are 40–90% stenosed in a proximal to a middle coronary segment on CCTA^{3,20}; **OR**
 - For evaluating multivessel disease and identifying culprit lesions seen on CCTA that may be causing symptoms; **OR**
 - For evaluating the physiologic severity of multiple lesions in a single vessel³; **OR**
- ◆ Preoperative evaluation when **ANY** of the following is **TRUE**:
 - Valve or other cardiac surgery
 - High risk vascular surgery (e.g., aneurysm repair)
 - Renal transplant or other solid organ transplant; **OR**
- ◆ Annual surveillance post-cardiac transplant^{34,35}; **OR**
- ◆ Repeat imaging (defined as repeat request following recent imaging of the same anatomic region with the same modality), in the absence of established guidelines, will be considered reasonable and necessary if **ANY** of the following is **TRUE**:
 - New or worsening symptoms, such that repeat imaging would influence treatment; **OR**
 - One-time clarifying follow-up of a prior indeterminate finding; **OR**
 - In the absence of change in symptoms, there is an established need for monitoring which would influence management.

Non-Indications

→ **Computed tomography coronary angiography (CCTA)** is not considered appropriate if **ANY** of the following is **TRUE**^{5,11}:

- ◆ If **ANY** of the following is **TRUE** if contrast is used:
 - History of anaphylactic allergic reaction to iodinated contrast media; **OR**
 - Renal insufficiency with no provided detailed guidelines; **OR**

- ◆ Normal coronary angiogram or CCTA with no stenosis or plaque within the last two years and stable symptoms; **OR**
- ◆ Normal stress test within the previous year (given adequate stress) with stable symptoms; **OR**
- ◆ If FFR is performed, it is not considered appropriate if **ANY** of the following conditions is **TRUE**^{3,21}:
 - The original CCTA was of suboptimal quality; **OR**
 - The patient is not a candidate for revascularization; **OR**
 - Coronary anatomy seen on CCTA is non-obstructive²⁰.

*NOTE: CT in patients with claustrophobia should be requested at the discretion of the ordering provider.

**NOTE: CT in pregnant patients should be requested at the discretion of the ordering provider and obstetric care provider.

Disclaimer on Radiation Exposure in Pediatric Population

Due to the heightened sensitivity of pediatric patients to ionizing radiation, minimizing exposure is paramount. At Cohere, we are dedicated to ensuring that every patient, including the pediatric population, has access to appropriate imaging following accepted guidelines. Radiation risk is dependent mainly on the patient's age at exposure, the organs exposed, and the patient's sex, though there are other variables. The following technical guidelines are provided to ensure safe and effective imaging practices:

Radiation Dose Optimization: Adhere to the lowest effective dose principle for pediatric imaging. Ensure that imaging protocols are specifically tailored for pediatric patients to limit radiation exposure.^{24,25}

Alternative Modalities: Prioritize non-ionizing imaging options such as ultrasound or MRI when clinically feasible, as they are less likely to expose the patient to ionizing radiation. For instance, MRI or ultrasound should be considered if they are more likely to provide an accurate diagnosis than CT, fluoroscopy, or radiography.^{24,25}

Cumulative Dose Monitoring: Implement systems to track cumulative radiation exposure in pediatric patients, particularly for those requiring

multiple imaging studies. Regularly reassess the necessity of repeat imaging based on clinical evaluation.^{24,25}

CT Imaging Considerations: When CT is deemed the best method for achieving a correct diagnosis, use the lowest possible radiation dose that still yields reliable diagnostic images.^{24,25}

Cohere Imaging Gently Guideline

The purpose of this guideline is to act as a potential override when clinically indicated to adhere to Imaging Gently and Imaging Wisely guidelines and As Low As Reasonably Possible (ALARA) principles.

Level of Care Criteria

Outpatient

Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
75574	Computed tomographic angiography (CTA), heart, coronary arteries and bypass grafts (when present); with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation)
75580	Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified healthcare professional

Medical Evidence

In the 2021 chest pain guideline for the American College of Cardiology, Gulati et al. give several recommendations for the use of coronary computed tomography angiography (CCTA), including for intermediate-risk patients with acute chest pain and no known coronary artery disease (CAD) who require diagnostic testing following a negative evaluation for acute coronary syndrome. Additionally, CCTA is a proven approach for evaluating patients with stable chest pain with a strong (Class 1) strength of recommendation³. The writers state that CCTA helps exclude atherosclerotic plaque and obstructive CAD. A recommendation was given for CCTA to diagnose obstructive CAD in patients at intermediate risk with acute pain and mildly abnormal previous stress testing. When evaluating patients in the emergency department with acute chest pain, CCTA may reduce the time to diagnosis and possible earlier safe discharge.³

Taylor et al. (2010) developed appropriate use criteria for cardiac computed tomography. The use of CCTA in low or intermediate-risk patients with pretest probability for CAD may be considered. Testing in high-risk patients, routinely repeating testing, and use for general cardiac screening were not viewed favorably. Lowest appropriateness ratings were assigned in urgent presentations with acute symptoms with suspicion of acute coronary syndrome, such as in definite myocardial infarction (MI), persistent ST-segment elevation on ECG (when MI excluded), and acute chest pain of uncertain cause prompting rule out of pulmonary embolism, aortic dissection and acute coronary syndrome.⁶

Driessen and colleagues (2019) published post hoc single-center study results comparing CCTA, FFR, and perfusion imaging for ischemia diagnosis for the American College of Cardiology. The 208 patients were enrolled with suspicion of CAD and underwent CCTA, SPECT, and PET scans with routine FFR study of all major coronary arteries. All patients were prospectively tested noninvasively and invasively with FFR within 2 weeks, regardless of their results. Of the 208 patients, the CCTA images of 75% of patients were entirely sufficient for evaluation by FFR_{CT}. The group concluded that FFR_{CT} showed high diagnostic performance for vessel-specific ischemia, provided that the CCTA

images were adequate for FFR evaluation. PET scanning yielded the highest diagnostic performance due to the often high rejection rate of the FFR_{CT}.⁹

References

1. Villines TC, American College of Cardiology. Coronary CTA should be the initial test in most patients with stable chest pain: PRO. American College of Cardiology. <https://www.acc.org/latest-in-cardiology/articles/2018/05/21/06/37/coronary-cta-pro>. Published May 21, 2018. Accessed July 1, 2024.
2. Poon M, Lesser JR, Biga C, et al. Current evidence and recommendations for coronary cta first in evaluation of stable coronary artery disease. *J Am Coll Cardiol*. 2020;76(11):1358-1362. doi: 10.1016/j.jacc.2020.06.078.
3. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain. *J Am Coll Cardiol*. 2021 Nov 30;78(22):e187-e285. doi: 10.1016/j.jacc.2021.07.053. PMID: 34756653.
4. American College of Radiology (ACR), North American Society of Cardiovascular Imaging (NASCI), Society for Pediatric Radiology (SPR). ACR-NASCI-SPR practice parameter for the performance and interpretation of cardiac computed tomography (CT) - resolution 45. Updated 2021. Accessed July 1, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CardiacCT.pdf>.
5. Abbara S, Blanke P, Maroules CD, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: A report of the Society of Cardiovascular Computed Tomography Guidelines Committee: Endorsed by the North American Society for Cardiovascular Imaging (NASCI). *J Cardiovasc Comput Tomogr*. 2016 Nov-Dec;10(6):435-449. doi: 10.1016/j.jcct.2016.10.002. PMID: 27780758.
6. Taylor AJ, Cerqueira M, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. *Circulation*. 2010 Nov 23;122(21):e525-55. doi: 10.1161/CIR.0b013e3181fcae66. PMID: 20975004.
7. Bellinge JW, Majeed K, Carr SS, et al. Coronary artery 18F-NaF PET analysis with the use of an elastic motion correction software. *J Nucl Cardiol*. 2020 Jun;27(3):952-961. doi: 10.1007/s12350-018-01587-7. PMID: 30684262.

8. Sanz J. Imaging of Coronary Disease Hemodynamic Significance: And the Winner Is... *J Am Coll Cardiol*. 2019 Jan 22;73(2):174-176. doi: 10.1016/j.jacc.2018.10.055. PMID: 30654889.
9. Driessen RS, Danad I, Stuijzand WJ, et al. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. *J Am Coll Cardiol*. 2019 Jan 22;73(2):161-173. doi: 10.1016/j.jacc.2018.10.056. PMID: 30654888.
10. Cheung BM. Coronary CT angiography and subsequent risk of myocardial infarction. *N Engl J Med*. 2019 Jan 17;380(3):299-300. doi: 10.1056/NEJMc1816189. PMID: 30653282 .
11. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2014 Feb 4;63(4):380-406. doi: 10.1016/j.jacc.2013.11.009. PMID: 24355759.
12. Narula J, Chandrashekar Y, Ahmadi A, et al. SCCT 2021 expert consensus document on coronary computed tomographic angiography: A report of the society of cardiovascular computed tomography. *J Cardiovasc Comput Tomogr*. 2021 May-Jun;15(3):192-217. doi: 10.1016/j.jcct.2020.11.001. PMID: 33303384; PMCID: PMC8713482.
13. Newby DE, Adamson PD, Berry C, et al. Coronary CT angiography and 5-year risk of myocardial infarction. *N Eng J Med*. 2018 Sep 6;379(10):924-933. doi: 10.1056/NEJMoA1805971. PMID: 30145934.
14. Expert Panel on Cardiac Imaging, Battle JC, Kirsch J, et al. ACR appropriateness criteria – chest pain, possible acute coronary syndrome. *J Am Coll Radiol*. 2020 May;17(5S):S55-S69. doi: 10.1016/j.jacr.2020.01.027. PMID: 32370978.
15. Expert Panel on Cardiac Imaging, Bolen MA, Saeedan MNB, et al. ACR appropriateness criteria – dyspnea-suspected cardiac origin (ischemia

- already excluded): 2021 update. *J Am Coll Radiol*. 2022 May;19(5S):S37–S52. doi: 10.1016/j.jacr.2022.02.014. PMID: 35550804.
16. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18):e895–e1032. doi: 10.1161/CIR.0000000000001063. PMID: 35363499. Erratum in: *Circulation*. 2022 May 3;145(18):e1033.
 17. Expert Panels on Cardiac Imaging and Neurological Imaging, Kligerman SJ, Bykowski J, et al. ACR appropriateness criteria – syncope. *J Am Coll Radiol*. 2021 May;18(5S):S229–S238. doi: 10.1016/j.jacr.2021.02.021. PMID: 33958116.
 18. Devitt M. Diagnosis of stable ischemic heart disease: Recommendations from the ACP. *Am Fam Phys*. 2013;88(7):469–470. <https://www.aafp.org/pubs/afp/issues/2013/1001/p469.html>.
 19. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;143(5):e72–e227. doi: 10.1161/CIR.0000000000000923. PMID: 33332150. Erratum in: *Circulation*. 2021 Feb 2;143(5):e229].
 20. Norgaard BL, Fairbairn TA, Safian RD, et al. Coronary CT angiography–derived fractional flow reserve testing in patients with stable coronary artery disease: Recommendations on interpretation and reporting. *Radiol Cardiothorac Imaging*. 2019 Nov 21;1(5):e190050. doi: 10.1148/ryct.2019190050. PMID: 33778528; PMCID: PMC7977999.
 21. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. *N Engl J Med*. 2018 Jul 19;379(3):250–259. doi: 10.1056/NEJMoal803538. PMID: 29785878.
 22. Edvardsen T, Asch FM, Davidson B, et al. Non-invasive imaging in coronary syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Eur Heart J Cardiovasc Imaging*. 2022 Jan 24;23(2):e6–e33. doi: 10.1093/ehjci/jeab244. PMID: 34751391.

23. United States Food and Drug Administration (FDA). De novo classification request for FFR_{CT} V. 1.4. (submission number DEN130045). Published November 6, 2013. Accessed July 1, 2024. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN130045.pdf.
24. The Image Gently Alliance. Procedures – cardiac imaging. Updated 2014. Accessed June 26, 2024. <https://www.imagegently.org/Procedures/Cardiac-Imaging>.
25. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): A guide for health care. Updated September 4, 2018. Accessed June 26, 2024. <https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/pediatric-ct-scans>.
26. Kjelle E, Brandsæter IØ, Andersen ER, Hofmann BM. Cost of low-value imaging worldwide: a systematic review. *Applied Health Economics and Health Policy*. 2024 Mar 1:1-7.
27. Thompson RC, Bateman TM, Blankstein R, Di Carli MF, Heydari B, Hung J, Kwong RY, Lindner JR, Nieman K, Dorbala S. A policy statement on cardiovascular test substitution and authorization: Principles of patient-centered noninvasive testing. *Journal of the American College of Cardiology*. 2021 Sep 28;78(13):1385-9.
28. Safavi KC, Li SX, Dharmarajan K, Venkatesh AK, Strait KM, Lin H, Lowe TJ, Fazel R, Nallamothu BK, Krumholz HM. Hospital variation in the use of noninvasive cardiac imaging and its association with downstream testing, interventions, and outcomes. *JAMA internal medicine*. 2014 Apr 1;174(4):546-53.
29. Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. *Life sciences*. 2020 Oct 15;259:118379.
30. Rudnick MR, Leonberg-Yoo AK, Litt HI, Cohen RM, Hilton S, Reese PP. The controversy of contrast-induced nephropathy with intravenous contrast: what is the risk?. *American Journal of Kidney Diseases*. 2020 Jan 1;75(1):105-13.
31. Summers LN, Harry ML, Colling KP. Evaluating our progress with trauma transfer imaging: repeat CT scans, incomplete imaging, and delayed definitive care. *Emergency Radiology*. 2021 Oct;28(5):939-48.
32. Nguyen T, Bhosale PR, Cassia L, Surabhi V, Javadi S, Milbourne A, Faria SC. Malignancy in pregnancy: Multimodality imaging and treatment. *Cancer*. 2023 May 15;129(10):1479-91.

33. Medscape Reference. Pre-test probability of CAD (CAD consortium). Updated 2020. Accessed September 11, 2024.
<https://reference.medscape.com/calculator/287/pre-test-probability-of-cad-cad-consortium>.
34. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *The Journal of heart and lung transplantation*. 2010 Aug 1;29(8):914-56.
35. Nous FM, Roest S, van Dijkman ED, Attrach M, Caliskan K, Brugts JJ, Nieman K, Hirsch A, Constantinescu AA, Manintveld OC, Budde RP. Clinical implementation of coronary computed tomography angiography for routine detection of cardiac allograft vasculopathy in heart transplant patients. *Transplant International*. 2021 Oct;34(10):1886-94.
36. Centers for Medicare & Medicaid Services. Local Coverage Determination L33423 Cardiac Computed Tomography & Angiography (CCTA). Revision Effective Date: March 13, 2025.
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33423&ver=55&bc=0>
37. Centers for Medicare & Medicaid Services. Local Coverage Determination L33559 Cardiac Computed Tomography & Angiography (CCTA). Published April 1, 2022. Accessed September 10, 2024.
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33559>
38. Centers for Medicare & Medicaid Services. Local Coverage Determination L35121 Cardiac Computed Tomography & Angiography (CCTA). Published November 30, 2023. Accessed September 10, 2024.
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35121&ver=31&keyword=breast+reconstruction&keywordType=any&areald=s20&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMD%2C6%2C3%2C5%2C1%2CF%2CP&contractOption=all&sortBy=relevance&bc=1>.
39. Centers for Medicare & Medicaid Services. Local Coverage Determination L33947 Cardiac Computed Tomography & Angiography (CCTA). Revision Effective Date October 3, 2024.

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33947&ver=23&bc=0>

40. Centers for Medicare & Medicaid Services. Local Coverage Determination L38839 Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease. Published April 25, 2021. Accessed September 10, 2024.

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38839&ver=9&bc=0>.

41. Centers for Medicare & Medicaid Services. Local Coverage Determination L38278 Non-Invasive Fractional Flow Reserve (FFR) for Stable Ischemic Heart Disease. Published August 14, 2022. Accessed September 10, 2024.

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38278&ver=24>.

42. Centers for Medicare & Medicaid Services. Local Coverage Determination L38615 Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease. Published September 18, 2022. Accessed September 10, 2024.

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38615&ver=11&keyword=valve%20replacement&keywordType=any&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

43. Centers for Medicare & Medicaid Services. Local Coverage Determination L38613 Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease. Published September 18, 2022. Accessed September 10, 2024.

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38613&ver=11&stateRegion=all&contractorNumber=all&lcdStatus=all&sortBy=title&bc=8>

44. Centers for Medicare & Medicaid Services. Local Coverage Determination L39075 Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease. Published April 1, 2023. Accessed September 10, 2024.

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39075>

45. Centers for Medicare & Medicaid Services. Local Coverage Determination L38771 Non-Invasive Fractional Flow Reserve (FFR) for

Ischemic Heart Disease. Published April 17, 2025.

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38771&ver=17&bc=0>

Clinical Guideline Revision History/Information

Original Date: September 12, 2024		
Review History		
Version 1.1	March 27, 2025	Updated policy per CMS revisions for 11/24/24 Updated Revision Date Updated Links and Bookmarks
Version 1.2	April 22, 2025	Updated policy per CMS revisions for 03/13/2025 Updated Revision Date Updated Links and References
Version 1.3	May 15, 2025	Updated policy per CMS revisions for 04/17/2025 Updated Revision Date Updated Links and References